FDA Turmoil: Trump Targets Top Commissioner

Signage of the U.S. Department of Health and Human Services and FDA

Washington’s latest power struggle shows how quickly a science agency can become a political chess piece—right when Americans need trustworthy drug and food oversight.

Quick Take

Multiple outlets report President Trump has signed off on plans to remove FDA Commissioner Dr. Marty Makary, though the move has not been finalized.
Makary’s 13-month tenure followed mass FDA firings under HHS Secretary Robert F. Kennedy Jr., leaving the agency strained and leadership-thin.
Flashpoints included flavored vape policy, the abortion pill mifepristone, and inconsistent reviews affecting drugmakers and patients.
The episode highlights a broader problem: when agencies churn leadership and staff, ordinary Americans pay the price through delays, uncertainty, and weakened confidence.

Trump’s Reported Decision Puts FDA Leadership Back in Flux

President Trump has reportedly approved plans to dismiss FDA Commissioner Dr. Martin “Marty” Makary, according to reporting published in early May 2026. The plan has been described as not yet final, and public statements have been inconsistent, including a reported May 6 claim from a White House official that Trump still supported Makary. As of May 10, Makary remained in the job, and the White House and agency leadership had not provided definitive public answers.

Makary entered the role in April 2025 amid unusual turbulence: HHS Secretary Robert F. Kennedy Jr. had fired roughly 3,500 FDA employees—about 20% of the workforce—shortly before Makary was sworn in. That kind of downsizing would test any commissioner. The result, according to accounts from inside and outside government, has been a year of heavy initiative-launching paired with churn, vacancies, and recurring disputes over what the FDA should prioritize.

Vapes, Mifepristone, and Drug Reviews: The Conflicts Behind the Headlines

Reporting on the potential firing points to several politically sensitive disputes. One involves flavored vapes, where Trump is described as opposing Makary’s posture after a meeting involving RJ Reynolds and direct engagement from the president. Another involves mifepristone, the abortion pill, where anti-abortion Republicans reportedly grew frustrated with delays tied to studies and restrictions. A third area involves uncertainty in drug review decisions, including rare-disease products that depend on consistent regulatory standards.

Those issues matter beyond the Beltway because they touch competing public demands: parents worried about youth nicotine use, voters divided over abortion policy, and families needing dependable timelines for drugs that can be life-changing. Conservatives often argue that agencies should enforce clear rules rather than improvise under political pressure, while liberals frequently warn about political interference in public health. The available reporting suggests both concerns are in play—without clear evidence, yet, of a clean path back to stability.

RFK Jr.’s FDA Shakeup Left a Weaker Bench for Any Commissioner

The staffing purge and leadership vacancies form the backdrop to Makary’s reported ouster. The health department has faced notable gaps, including the absence of some permanent leadership roles and interim management in key FDA areas. That matters because the FDA is not just a public-facing regulator; it is also a complex operational machine that depends on institutional memory. When experienced reviewers and managers leave, drug and device decisions can slow, become inconsistent, or spark more disputes.

Makary’s tenure reportedly included numerous initiatives—ranging from efforts to shorten reviews to crackdowns on certain advertising and pressure campaigns related to food dyes—yet these efforts were described as paired with internal “flip-flops” and turnover. A conservative takeaway is straightforward: reform is not the same as disruption. If Washington wants leaner government that still works, it has to separate trimming bureaucracy from damaging the capacity to do core jobs Americans actually expect.

What This Means for Patients, Markets, and Trust in Government

If the plan to remove Makary becomes official, the next question is who takes over—and how quickly the administration can restore predictability. Reports have mentioned possible interim choices with prior government experience. The stakes are practical: user-fee negotiations, drug approvals, and safety communications all depend on steady leadership. For industry, uncertainty can mean delayed investments; for patients, it can mean delayed access. For the public, it can mean another hit to confidence.

The larger significance is that the FDA has become a symbol of something many Americans across parties now believe: the federal government struggles to execute basic responsibilities without getting pulled into constant internal warfare. Conservatives who want limited government still need competent government where it matters—especially with food and drug safety. Liberals who fear politicization also need rules applied consistently. Without that shared baseline, every controversy becomes another elite fight with everyday consequences.